Xcout Intel
Enzymatica
Enzymatica develops health solutions and barrier technology products, such as the ColdZyme mouth spray, designed to support the body's defense against viruses and micro-organisms. The company serves consumers looking to prevent or alleviate common cold symptoms and respiratory infections.
Subscribe to see Enzymatica’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Enzymatica at a glance
Enzymatica is a health care company headquartered in Sweden. Xcout tracks 4 named people at Enzymatica, including Bengt Baron (Styrelseledamot).
Enzymatica leadership
- Bengt BaronStyrelseledamot
- Gudmundur PalmasonStyrelseledamot
- Helene WillbergStyrelseledamot (ordförande revisionsutskottet)
- Mats AnderssonStyrelseledamot (ordförande ersättningsutskottet)
Enzymatica competitors
A few of Enzymatica's closest competitors — see the full list of competitors and alternatives →
Biograil ApS is a Copenhagen-based pre-clinical stage pharmaceutical and biotech company developing a unique oral device for the delivery of therapeutics. The company collaborates with major industry partners like CSL.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Eterna Regeneratives develops regenerative biomaterials and protein-derived scaffolds designed for mineralisation and tissue regeneration. The company's initial applications focus on oral health and enamel repair through professional consumer dental care formats, as well as bone regeneration for orthopaedic and bone grafting uses.
Biora Therapeutics is a U.S. biotechnology company developing ingestible, device-based platforms for delivering biologic medicines to targeted areas of the gastrointestinal tract and into systemic circulation. Its technologies are intended for use by pharmaceutical and biotechnology companies developing oral or targeted biologic therapies.
UPSA is a French pharmaceutical laboratory that manufactures and provides over-the-counter medications, medical devices, and dietary supplements to help patients treat common, everyday ailments. The company operates across six main therapeutic areas, including pain and fever, ENT, digestion, sleep, women's health, and vitality.
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Get Enzymatica's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Enzymatica in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access